Transcept Seeks $40.5M to Attack Trio of Business Goals
By Marie Powers
Friday, April 27, 2012
After moving insomnia drug Intermezzo (zolpidem tartrate) through the approval process, Transcept Pharmaceuticals Inc. is seeking to raise $40.5 million in an underwritten public offering of 4.5 million shares of common stock as the company turns its attention to TO-2061, a low-dose formulation of ondansetron as adjunctive treatment for obsessive compulsive disorder (OCD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.